Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis.

Xue Shang, Kangle Guo, Fenfen E, Xinxin Deng, Yongsheng Wang, Ziyi Wang, Yanan Wu, Meng Xu, Chaoqun Yang, Xiuxia Li, Kehu Yang
Author Information
  1. Xue Shang: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  2. Kangle Guo: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  3. Fenfen E: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  4. Xinxin Deng: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  5. Yongsheng Wang: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  6. Ziyi Wang: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  7. Yanan Wu: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  8. Meng Xu: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  9. Chaoqun Yang: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  10. Xiuxia Li: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.
  11. Kehu Yang: Health Technology Assessment Center/Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.

Abstract

A network meta-analysis based on randomized controlled trials was conducted to investigate the effects of pharmacological interventions on smoking cessation. English databases were searched to obtain randomized controlled trials reporting the effect of pharmacological interventions on smoking cessation. The risk of bias for the included trials was assessed using Cochrane Handbook tool. Stata 15.1 software was used to perform network meta-analysis, and GRADE approach was used to assess the evidence credibility on the effects of different interventions on smoking cessation. A total of 159 studies involving 60,285 smokers were included in the network meta-analysis. The analysis involved 15 interventions and which yielded 105 pairs of comparisons. Network meta-analysis showed that varenicline was more helpful for smoking cessation than other monotherapies, such as nicotine replacement therapy [Odds Ratio (OR) = 1.42, 95% confidence interval (CI) (1.16, 1.73)] and bupropion [OR = 1.52, 95% CI (1.22, 1.89)]. Furthermore, combined interventions were superior to monotherapy in achieving smoking cessation, such as varenicline plus bupropion over bupropion [OR = 2.00, 95% CI (1.11, 3.61)], varenicline plus nicotine replacement therapy over nicotine replacement therapy [OR = 1.84, 95% CI (1.07, 3.18)], and nicotine replacement therapy plus mecamylamine over naltrexone [OR = 6.29, 95% CI (1.59, 24.90)]. Finally, the surface under the cumulative ranking curve value indicated that nicotine replacement therapy plus mecamylamine had the greatest probability of becoming the best intervention. Most pharmacological interventions demonstrated a benefit in smoking cessation compared with placebo, whether monotherapy or combination therapy. Moreover, confirmed evidence suggested that some combination treatments, such as varenicline plus bupropion and nicotine replacement therapy plus mecamylamine have a higher probability of being the best smoking cessation in.

Keywords

References

  1. Monaldi Arch Chest Dis. 2013 Mar;79(1):27-32 [PMID: 23741943]
  2. J Clin Epidemiol. 2020 Jun;122:142-152 [PMID: 32058069]
  3. Int J Chron Obstruct Pulmon Dis. 2022 May 06;17:1107-1120 [PMID: 35573655]
  4. BMC Public Health. 2018 May 24;18(1):655 [PMID: 29793454]
  5. Cochrane Database Syst Rev. 2013 May 31;(5):CD009329 [PMID: 23728690]
  6. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003086 [PMID: 17054160]
  7. Eur Respir J. 2009 Sep;34(3):634-40 [PMID: 19357145]
  8. BMJ Open. 2014 Mar 14;4(3):e004393 [PMID: 24633528]
  9. Cochrane Database Syst Rev. 2019 Apr 18;4:CD013308 [PMID: 30997928]
  10. BMC Med Res Methodol. 2019 Apr 24;19(1):86 [PMID: 31018836]
  11. Epidemiol Health. 2017 Oct 27;39:e2017047 [PMID: 29092392]
  12. Compr Psychiatry. 2019 Nov;95:152125 [PMID: 31669972]
  13. Nicotine Tob Res. 2012 Sep;14(9):1035-9 [PMID: 22345320]
  14. J Clin Epidemiol. 2011 Apr;64(4):383-94 [PMID: 21195583]
  15. Environ Res. 2017 Jan;152:496-502 [PMID: 27712837]
  16. Respir Med. 2004 Sep;98(9):805-15 [PMID: 15338790]
  17. Int J Clin Pract. 2021 Nov;75(11):e14594 [PMID: 34228852]
  18. Addict Behav. 2016 Feb;53:175-80 [PMID: 26547043]
  19. Lancet Oncol. 2021 Sep;22(9):1217 [PMID: 34364410]
  20. Eur Respir Rev. 2013 Mar 1;22(127):37-43 [PMID: 23457163]
  21. Can Fam Physician. 2021 Oct;67(10):743-745 [PMID: 34649897]
  22. Drug Alcohol Depend. 2019 Dec 1;205:107631 [PMID: 31678838]
  23. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253 [PMID: 23450574]
  24. J Clin Epidemiol. 2011 Dec;64(12):1294-302 [PMID: 21803546]
  25. Semin Respir Crit Care Med. 2015 Aug;36(4):491-507 [PMID: 26238637]
  26. Expert Opin Pharmacother. 2003 Apr;4(4):533-40 [PMID: 12667116]
  27. Lancet Psychiatry. 2020 Sep;7(9):762-774 [PMID: 32828166]
  28. Cochrane Database Syst Rev. 2018 May 31;5:CD000146 [PMID: 29852054]
  29. Ann Pharmacother. 2014 Nov;48(11):1445-55 [PMID: 25095786]
  30. Expert Opin Drug Discov. 2018 Jul;13(7):671-683 [PMID: 29587555]
  31. Ann Intern Med. 2015 Jun 2;162(11):777-84 [PMID: 26030634]
  32. J Epidemiol Community Health. 2010 Jun;64(6):554-6 [PMID: 20466721]
  33. Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1): [PMID: 28093398]
  34. J Evid Based Med. 2018 Aug;11(3):176-183 [PMID: 29266878]
  35. J Clin Epidemiol. 2011 Dec;64(12):1283-93 [PMID: 21839614]
  36. J Stat Softw. 2017 Aug;80: [PMID: 28883783]
  37. Expert Opin Pharmacother. 2021 May;22(7):835-847 [PMID: 33372557]
  38. Health Technol Assess. 2021 Oct;25(59):1-224 [PMID: 34668482]
  39. Med J Islam Repub Iran. 2016 Jul 13;30:397 [PMID: 27579287]
  40. BMJ. 2019 Aug 28;366:l4898 [PMID: 31462531]
  41. Addiction. 2016 Apr;111(4):599-612 [PMID: 26594837]
  42. Can J Cardiol. 2013 Dec;29(12):1704-11 [PMID: 24267809]
  43. Am Heart J. 2005 Apr;149(4):565-72 [PMID: 15990735]
  44. J Evid Based Med. 2019 May;12(2):105-112 [PMID: 30511474]
  45. J Clin Epidemiol. 2022 Jan;141:64-73 [PMID: 34520849]
  46. J Addict Res Ther. 2011 Dec 20;S4(1): [PMID: 22514788]
  47. BMC Cardiovasc Disord. 2021 Dec 3;21(1):576 [PMID: 34861819]
  48. Lancet. 2018 Nov 10;392(10159):1923-1994 [PMID: 30496105]
  49. Pharmacol Res. 2021 Apr;166:105478 [PMID: 33549729]
  50. Nicotine Tob Res. 2020 Oct 8;22(10):1860-1866 [PMID: 32484870]
  51. Dig Surg. 2001;18(3):163-4 [PMID: 11464002]
  52. Int J Epidemiol. 2013 Oct;42(5):1464-75 [PMID: 24057999]
  53. Cochrane Database Syst Rev. 2020 Mar 4;3:CD010078 [PMID: 32129504]
  54. Can J Cardiol. 2010 Feb;26(2):73-9 [PMID: 20151052]
  55. Cochrane Database Syst Rev. 2014 Jan 08;(1):CD000031 [PMID: 24402784]
  56. J Evid Based Med. 2020 Feb;13(1):25-33 [PMID: 32112515]
  57. Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097 [PMID: 31570931]
  58. PLoS One. 2014 Mar 26;9(3):e92508 [PMID: 24671099]
  59. J Clin Epidemiol. 2011 Apr;64(4):407-15 [PMID: 21247734]

Word Cloud

Created with Highcharts 10.0.01smokingcessationinterventionstherapymeta-analysisnicotinereplacementplusnetwork=95%CI]vareniclinebupropion[ORtrialspharmacologicalmecamylaminerandomizedcontrolledeffectsincluded15usedevidencemonotherapy3probabilitybestcombinationreviewbasedconductedinvestigateEnglishdatabasessearchedobtainreportingeffectriskbiasassessedusingCochraneHandbooktoolStatasoftwareperformGRADEapproachassesscredibilitydifferenttotal159studiesinvolving60285smokersanalysisinvolvedyielded105pairscomparisonsNetworkshowedhelpfulmonotherapies[OddsRatioOR42confidenceinterval1673522289Furthermorecombinedsuperiorachieving2001161840718naltrexone629592490FinallysurfacecumulativerankingcurvevalueindicatedgreatestbecominginterventiondemonstratedbenefitcomparedplacebowhetherMoreoverconfirmedsuggestedtreatmentshigherinPharmacologicalcessation:systematicSystematicpharmacotherapytobacco

Similar Articles

Cited By